No quarterly revenue total was found in DRUGS MADE IN AMERICA ACQUISITION II CORP.'s SEC filings.
Drugs Made In America Acquisition II Corp. (DMII) files with the SEC under industry code 6770, Blank Checks. As of Jun 30, 2026 it held $174,974 in cash and investments and $450,000 in total debt.
Revenue
—
Net income
$4.40M
+1.4% vs prior quarter
Operating cash flow
$-172,746
-68.5% vs prior quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
63.70M
+0.0% vs prior quarter
Net cash
$-275,026
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Blank Checks (SIC 6770)
- Listed as
- DMII (Nasdaq), DMIIR (Nasdaq), DMIIU (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2040475
Other Blank Checks companies
- EQV Ventures Acquisition Corp. II EVAC
- Bain Capital GSS Investment Corp. BCSS
- Cantor Equity Partners IV, Inc. CEPF
- Churchill Capital Corp XII CXII
- American Exceptionalism Acquisition Corp. A AEXA
- New America Acquisition I Corp. NWAX
- Ares Acquisition Corp III AAC
- Mountain Lake Acquisition Corp. II MLAA
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|
| Operating income | -$112,227 | -$132,030 | -$235,472 | -$155,513 |
| Net income | $4.4M | $4.3M | $4.3M | -$46,158 |
| Operating cash flow | -$172,746 | -$102,503 | -$314,864 | -$703,367 |
| Total assets | $514.1M | $509.7M | $505.0M | $501.0M |
| Total liabilities | $18.1M | $18.2M | $17.8M | $18.2M |
| Stockholders' equity | -$17.9M | -$17.8M | -$17.8M | -$17.3M |
| Cash and investments | $174,974 | $347,720 | $223 | $315,087 |
| Total debt | $450,000 | $450,000 | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
Apr 28, 2026 | Apr 22, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
Apr 3, 2026 | Mar 24, 2026 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Mar 17, 2026 | Mar 11, 2026 |
All 45 Drugs Made In America Acquisition II Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.